<?xml version="1.0" encoding="UTF-8"?>
<ref id="B24-ijms-22-01285">
 <label>24.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Hwang</surname>
    <given-names>K.-S.</given-names>
   </name>
   <name>
    <surname>Kan</surname>
    <given-names>H.</given-names>
   </name>
   <name>
    <surname>Kim</surname>
    <given-names>S.S.</given-names>
   </name>
   <name>
    <surname>Chae</surname>
    <given-names>J.S.</given-names>
   </name>
   <name>
    <surname>Yang</surname>
    <given-names>J.Y.</given-names>
   </name>
   <name>
    <surname>Shin</surname>
    <given-names>D.-S.</given-names>
   </name>
   <name>
    <surname>Ahn</surname>
    <given-names>S.H.</given-names>
   </name>
   <name>
    <surname>Ahn</surname>
    <given-names>J.H.</given-names>
   </name>
   <name>
    <surname>Cho</surname>
    <given-names>J.-H.</given-names>
   </name>
   <name>
    <surname>Jang</surname>
    <given-names>I.-S.</given-names>
   </name>
  </person-group>
  <article-title>Efficacy and pharmacokinetics evaluation of 4-(2-chloro-4-fluorobenzyl)-3-(2-thienyl)-1,2,4-oxadiazol-5(4H)-one (GM-90432) as an anti-seizure agent</article-title>
  <source>Neurochem. Int.</source>
  <year>2020</year>
  <volume>141</volume>
  <fpage>104870</fpage>
  <pub-id pub-id-type="doi">10.1016/j.neuint.2020.104870</pub-id>
  <pub-id pub-id-type="pmid">33035603</pub-id>
 </element-citation>
</ref>
